唑来膦酸致老年女性骨质疏松症患者急性前葡萄膜炎1例被引量：5

Acute anterior uveitis induced by zoledronic acid in an old osteoporosis woman

导出

摘要唑来膦酸（zoledronic acid）是目前国内最常用的双膦酸盐类药物之一,它与骨骼羟磷灰石有高亲和的结合力,能特异性地结合到骨转换活跃的骨表面,抑制破骨细胞功能,减少骨吸收,降低椎体、髋部和其他部位骨折的风险。本院在使用唑来膦酸过程中,有1例老年女性骨质疏松症患者出现不常见的急性前葡萄膜炎（acute anterior uveitis,AAU）,现报道如下。

作者边平达寿张轩邵玉红

机构地区浙江省人民医院骨质疏松诊疗中心浙江省人民医院药学部浙江省人民医院眼科

出处《中国新药与临床杂志》 CAS CSCD 北大核心 2016年第6期451-452,共2页 Chinese Journal of New Drugs and Clinical Remedies

基金浙江省医药卫生平台重点资助计划项目(2016ZDA002) 浙江省人民医院优秀青年人员科研启动基金项目(zry2015C002)

关键词唑来膦酸葡萄膜炎前骨质疏松 zoledronic acid uveitis, anterior osteoporosis

分类号 R773 [医药卫生—眼科] R977 [医药卫生—药品]

引文网络
相关文献

参考文献6

1娄振凯,李春海,叶伟,丁悦,朱伟荣,任晋可.注射用唑来膦酸治疗绝经后骨质疏松36例[J].中国新药与临床杂志,2012,31(5):247-250. 被引量：12
2BLACK DM, REID IR, CAULEY JA, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT)[J]. J Bone Miner Res, 2015, 30(5): 934-944.
3杨培增.葡萄膜疾病[M]//惠延年.眼科学.5版.北京:人民卫生出版社,2002:125-130.
4IDREES AS, SUGIE T, INOUE C, et al. Comparison of γδT cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid[J]. Cancer Sci, 2013, 104(5) : 536-542.
5FREITAS-NETO CA, de OLIVEIRA FAGUNDES WB, RIBEIRO M Jr, et al. Unilateral uveitis with vitreous haze following zoledronic acid therapy for osteoporosis[J]. Semin Ophthalmol, 2015, 30 (3) : 232-234.
6PATEL DV, BOLLAND M, NISA Z, et ol. Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial[J]. Osteoporos Int, 2015, 26 (2) : 499-503.

二级参考文献16

1彭六保,崔巍.唑来膦酸的临床应用研究进展[J].中国新药与临床杂志,2007,26(3):237-240. 被引量：36
2DENNISON E,MOHAMED MA,COOPER C. Epidemiology of osteoporosis[J]. Rheum Dis Clin North Am, 2006, 32(4): 617-629..
3EPSTEIN S. Update of current therapeutic options for the treatment of postmenopausal osteoporosis[J]. Clin Ther, 2006, 28 (2): 151-173.
4NIH consensus development panel on osteoporosis prevention, diagnosis, and therapy. Osteoporosis prevention, diagnosis, and therapy[J]. JAMA, 2001, 285(6): 785-795.
5WAINWRIGHT SA, MARSHALL LM, ENSRUD KE, et al. Hip fracture in women without osteoporosis[J]. J Clin Endocrinol Metab, 2005, 90(5): 2787-2793.
6TOSTESON AN, GROVE MR, HAMMOND CS, et al. Early discontinuation of treatment for osteoporosis[J]. Am J Med, 2003, 115(3): 209-216.
7NANCOLLS GH, TANG R, PHIPPS RJ, et al. Novel insights into actions of bisphosphonates on bone: differences interactions with hydroxyapatite[J]. Bone, 2006, 38(5): 617-627.
8DUNFORD JE, THOMPSON K, COXON FP, et al. Structure- activity relationships for inhibition of farnsyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates[J]. J Pharmacol Exp Ther, 2001, 296(2): 235-242.
9MEUNIER PJ, BOIVIN G. Bone mineral density reflects bone mass but also degree of mineralization of bone: therapeutic implications[J]. Bone, 1997, 21 (5) : 373-377.
10BLACK DM, DELMAS PD, EASTELL R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis[J]. N Engl J Med, 2007, 356(18): 1809-1822.